Literature DB >> 20625723

The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging.

Walter Jentzen1, Dorothee Balschuweit, Jochen Schmitz, Lutz Freudenberg, Ernst Eising, Thomas Hilbel, Andreas Bockisch, Alexander Stahl.   

Abstract

PURPOSE: A serious side effect of high-activity radioiodine therapy in the treatment of differentiated thyroid cancer is radiogenic salivary gland damage. This damage may be diminished by lemon-juice-induced saliva flow immediately after 131I administration. The aim of this study was to assess the effect of chewing lemon slices on the absorbed (radiation) doses to the salivary glands.
METHODS: Ten patients received (pretherapy) 124I PET(/CT) dosimetry before their first radioiodine therapy. The patients underwent a series of six PET scans at 0.5, 1, 2, 4, 48 and ≥96 h and one PET/CT scan at 24 h after administration of 27 MBq 124I. Blood samples were also collected at about 2, 4, 24, 48, and 96 h. Contrary to the standard radioiodine therapy protocol, the patients were not stimulated with lemon juice. Specifically, the patients chewed no lemon slices during the pretherapy procedure and neither ate food nor drank fluids until after completion of the last PET scan on the first day. Organ absorbed doses per administered 131I activity (ODpAs) as well as gland and blood uptake curves were determined and compared with published data from a control patient group, i.e. stimulated per the standard radioiodine therapy protocol. The calculations for both groups used the same methodology.
RESULTS: A within-group comparison showed that the mean ODpA for the submandibular glands was not significantly different from that for the parotid glands. An intergroup comparison showed that the mean ODpA in the nonstimulation group averaged over both gland types was reduced by 28% compared to the mean ODpA in the stimulation group (p=0.01). Within each gland type, the mean ODpA reductions in the nonstimulation group were statistically significant for the parotid glands (p=0.03) but not for the submandibular glands (p=0.23). The observed ODpAs were higher in the stimulation group because of increased initial gland uptake rather than group differences in blood kinetics.
CONCLUSION: The 124I PET(/CT) salivary gland dosimetry indicated that lemon juice stimulation shortly after 131I administration in radioiodine therapy increases the absorbed doses to the salivary glands.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20625723     DOI: 10.1007/s00259-010-1532-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  11 in total

Review 1.  Radioactive iodine and the salivary glands.

Authors:  Susan J Mandel; Louis Mandel
Journal:  Thyroid       Date:  2003-03       Impact factor: 6.568

2.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

3.  Salivary gland toxicity after radioiodine therapy for thyroid cancer.

Authors:  S Hyer; A Kong; B Pratt; C Harmer
Journal:  Clin Oncol (R Coll Radiol)       Date:  2007-02       Impact factor: 4.126

4.  Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?

Authors:  Kunihiro Nakada; Tetsuya Ishibashi; Toshiki Takei; Kenji Hirata; Katsura Shinohara; Seiichi Katoh; Sonji Zhao; Nagara Tamaki; Yasushi Noguchi; Shiro Noguchi
Journal:  J Nucl Med       Date:  2005-02       Impact factor: 10.057

5.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

6.  Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems.

Authors:  Walter Jentzen; Reiner Weise; Jürgen Kupferschläger; Lutz Freudenberg; Wolfgang Brandau; Ronald Bares; Wolfgang Burchert; Andreas Bockisch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-10       Impact factor: 9.236

7.  Sialadenitis following I-131 therapy for thyroid carcinoma: concise communication.

Authors:  P Allweiss; G D Braunstein; A Katz; A Waxman
Journal:  J Nucl Med       Date:  1984-07       Impact factor: 10.057

8.  Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer.

Authors:  L S Freudenberg; G Antoch; W Jentzen; R Pink; J Knust; R Görges; S P Müller; A Bockisch; J F Debatin; W Brandau
Journal:  Eur Radiol       Date:  2004-06-30       Impact factor: 5.315

9.  Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.

Authors:  Walter Jentzen; Robert F Hobbs; Alexander Stahl; Jochen Knust; George Sgouros; Andreas Bockisch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

10.  Salivary gland protection with sialagogues: a case study.

Authors:  Douglas Van Nostrand; Frank Atkins; Varalakshmi V Bandaru; Shyam P Chennupati; Shari Moreau; Kenneth Burman; Leonard Wartofsky
Journal:  Thyroid       Date:  2009-09       Impact factor: 6.568

View more
  23 in total

Review 1.  Radioiodine Treatment and Thyroid Hormone Suppression Therapy for Differentiated Thyroid Carcinoma: Adverse Effects Support the Trend toward Less Aggressive Treatment for Low-Risk Patients.

Authors:  E N Klein Hesselink; T P Links
Journal:  Eur Thyroid J       Date:  2015-06-11

Review 2.  The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy.

Authors:  Scott A Rivkees; Ernest L Mazzaferri; Frederik A Verburg; Christoph Reiners; Markus Luster; Christopher K Breuer; Catherine A Dinauer; Robert Udelsman
Journal:  Endocr Rev       Date:  2011-08-31       Impact factor: 19.871

Review 3.  Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer.

Authors:  Lutz S Freudenberg; Walter Jentzen; Alexander Stahl; Andreas Bockisch; Sandra J Rosenbaum-Krumme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

4.  Reduction of Salivary Gland Damage During Radioiodine Therapy for Differentiated Thyroid Cancers.

Authors:  Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2020-05-12

Review 5.  Differentiated thyroid cancer-personalized therapies to prevent overtreatment.

Authors:  Markus Luster; Theresia Weber; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2014-07-01       Impact factor: 43.330

Review 6.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

7.  Monte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PET.

Authors:  R F Hobbs; W Jentzen; A Bockisch; G Sgouros
Journal:  Q J Nucl Med Mol Imaging       Date:  2013-03       Impact factor: 2.346

8.  Radioactive iodine: An unappreciated threat to salivary gland function.

Authors:  G Sunavala-Dossabhoy
Journal:  Oral Dis       Date:  2018-03       Impact factor: 3.511

Review 9.  Sialadenitis as a complication of radioiodine therapy in patients with thyroid cancer: where do we stand?

Authors:  Marios Adramerinas; Dimitrios Andreadis; Konstantinos Vahtsevanos; Athanasios Poulopoulos; Kalliopi Pazaitou-Panayiotou
Journal:  Hormones (Athens)       Date:  2021-06-18       Impact factor: 2.885

10.  Early Quantification of Salivary Gland Function after Radioiodine Therapy.

Authors:  Karan Singh Tanwar; Nivedita Rana; Bhagwant Rai Mittal; Anish Bhattacharya
Journal:  Indian J Nucl Med       Date:  2021-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.